Porcine Reproductive and Respiratory Syndrome Coinfections with Bacterial Pathogens in Swine: Pathogenesis Diagnostics and Control

Abstract

Porcine reproductive and respiratory syndrome virus (PRRSV) represents one of the most economically significant pathogens affecting global swine production. The clinical and economic impact of PRRSV is substantially amplified through synergistic interactions with secondary bacterial pathogens that constitute the porcine respiratory disease complex (PRDC). This review examines the molecular mechanisms underlying PRRSV-mediated immune suppression that facilitates bacterial colonization, the diagnostic challenges inherent in mixed infections, and evidence-based control strategies. Particular emphasis is placed on Streptococcus suis and Mycoplasma hyopneumoniae as predominant secondary invaders. Recent advances in multiplex molecular diagnostics, metagenomic surveillance, and immunomodulatory interventions are evaluated in the context of antimicrobial stewardship and herd health management.

1. Introduction

Porcine reproductive and respiratory syndrome (PRRS) emerged in the late 1980s as a novel disease syndrome characterized by reproductive failure in breeding herds and respiratory distress in growing pigs. The etiological agent, PRRSV, is an enveloped positive-sense single-stranded RNA virus classified within the family Arteriviridae genus Betaarterivirus. Two distinct genotypes exist: PRRSV-1 (European prototype) and PRRSV-2 (North American prototype), which share approximately 60 percent nucleotide identity yet induce similar clinical syndromes.

The economic burden of PRRS in the United States alone has been estimated at approximately 664 million USD annually when accounting for production losses, control measures, and veterinary costs. A critical determinant of this economic impact is the propensity of PRRSV to predispose infected pigs to secondary bacterial pneumonia. The resultant polymicrobial disease entity, termed the porcine respiratory disease complex (PRDC), involves intricate interactions between viral and bacterial pathogens, host immune responses, and environmental stressors.

Large-scale epidemiological investigations have quantified the co-occurrence patterns of respiratory pathogens in commercial swine populations. A macroepidemiologic assessment of swine disease co-occurrences in the United States demonstrated significant positive associations between PRRSV detection and multiple bacterial pathogens including Mycoplasma hyopneumoniae, Actinobacillus pleuropneumoniae, and Streptococcus suis [4]. Similarly, a large-scale landscape analysis of porcine respiratory disease complex-associated pathogens in Spanish swine production confirmed PRRSV as a central node in pathogen co-detection networks with bacterial agents [2]. These population-level observations underscore the clinical relevance of understanding viral-bacterial synergy at the molecular and cellular levels.

2. Molecular Mechanisms of Viral-Bacterial Synergy

2.1 PRRSV-Mediated Immune Suppression

PRRSV exhibits a restricted tropism for porcine macrophages, particularly the subpopulation expressing the scavenger receptor CD163 and the sialoadhesin receptor (Sn/SIGLEC1). Infection of alveolar macrophages (AMs) and pulmonary intravascular macrophages (PIMs) results in profound functional impairment of these critical innate immune cells. The mechanisms of macrophage dysfunction include:

• Impaired phagocytosis and bacterial clearance: PRRSV infection reduces the expression of surface receptors involved in pathogen recognition including MARCO (macrophage receptor with collagenous structure) and TLR2/TLR4 complexes. This diminishes the capacity of AMs to internalize and kill opsonized bacteria.
• Dysregulated cytokine production: Infected macrophages exhibit skewed cytokine profiles characterized by suppressed type I interferon (IFN-α/β) responses and elevated interleukin-10 (IL-10) production. The resulting anti-inflammatory milieu inhibits Th1 polarization and macrophage activation required for intracellular bacterial control.
• Induction of apoptosis: PRRSV triggers both intrinsic and extrinsic apoptotic pathways in macrophages through caspase-3 activation and mitochondrial membrane depolarization. Premature depletion of AMs creates a cellular niche for bacterial proliferation.

Recent work has elucidated a novel mechanism by which PRRSV actively remodels the host cell cytoskeleton and membrane proteome to facilitate bacterial adhesion and invasion. Liu et al. demonstrated that PRRSV infection reorganizes actin filaments and redistributes membrane proteins including integrins and ICAM-1, creating a cellular phenotype that enhances binding and internalization of Streptococcus suis and other bacterial pathogens [7]. This active remodeling represents a direct viral contribution to bacterial pathogenesis beyond passive immune suppression.

2.2 Modulation of Nuclear Factor-κB Signaling

The nuclear factor-κB (NF-κB) pathway serves as a central regulator of proinflammatory gene expression in response to pathogen-associated molecular patterns (PAMPs). PRRSV encodes multiple non-structural proteins (nsps) that antagonize NF-κB activation at distinct steps. Nsp1α, Nsp1β, Nsp2, Nsp4, and Nsp11 have all been implicated in interferon antagonism and NF-κB inhibition through mechanisms including:

• Degradation of the NF-κB essential modulator (NEMO/IKKγ)
• Inhibition of IκBα phosphorylation and degradation
• Sequestration of transcription factors in the cytoplasm
• Promotion of deubiquitination of signaling intermediates

Tang et al. investigated the consequences of genetic modification of PRRSV-2 to suppress NF-κB activation during coinfection with secondary bacterial pathogens [8]. Their findings indicate that while NF-κB suppression attenuates proinflammatory cytokine storms, it concurrently impairs bacterial clearance mechanisms, creating a complex trade-off in disease outcomes. A clinically attenuated double-mutant PRRSV-2 that does not prompt overexpression of proinflammatory cytokines during co-infection with a secondary pathogen was subsequently characterized, demonstrating that balanced immune modulation rather than complete suppression may be desirable for vaccine design [11].

2.3 Microbiome Dysbiosis and Virulence Factor Expression

PRRSV infection induces significant perturbations in the respiratory microbiome composition and functional capacity. Metagenomic and metatranscriptomic analyses of pigs within the PRDC have revealed that viral-bacterial co-infections correlate with enrichment of virulence factor genes including adhesins, toxins, and antimicrobial resistance determinants [5]. The functional microbiome of PRRSV-infected pigs shows increased expression of bacterial genes involved in iron acquisition, capsule synthesis, and biofilm formation, suggesting that the virus-altered host environment selects for more pathogenic bacterial phenotypes.

Changes in the nasal microbiota following single or co-infection with PRRSV and swine influenza A virus demonstrate that viral infection reduces microbial diversity and enriches for opportunistic pathogens including Streptococcus spp. and Pasteurella spp. [14]. These microbiome shifts persist beyond the acute viral phase, creating a prolonged window of susceptibility to bacterial pneumonia.

3. Principal Bacterial Coinfecting Agents

3.1 Streptococcus suis

Streptococcus suis is a Gram-positive encapsulated bacterium classified into 35 serotypes based on capsular polysaccharide antigens. Serotype 2 (SS2) represents the most prevalent and virulent strain associated with systemic disease in pigs and zoonotic infections in humans. The pathogenesis of S. suis in PRRSV-coinfected pigs involves multiple virulence determinants:

Lipid profiling studies have revealed distinct metabolic signatures in S. suis serotype 2 during coinfection with PRRSV, including alterations in membrane phospholipid composition that may affect host-pathogen interactions and antibiotic susceptibility [1]. The synergistic pathogenicity of PRRSV and S. suis is further evidenced by increased bacterial loads in lung tissue, enhanced systemic dissemination, and elevated mortality compared to single infections.

3.2 Mycoplasma hyopneumoniae

Mycoplasma hyopneumoniae is a wall-less bacterium lacking peptidoglycan that adheres to ciliated respiratory epithelium via specialized tip organelles containing adhesins P97, P102, and P146. As the etiological agent of enzootic pneumonia, M. hyopneumoniae causes ciliostasis, epithelial hyperplasia, and lymphoid hyperplasia in the bronchial-associated lymphoid tissue (BALT).

The interaction between PRRSV and M. hyopneumoniae is characterized by:

• Prolonged viral shedding: M. hyopneumoniae coinfection extends the duration of PRRSV viremia and lung replication
• Enhanced lymphoid hyperplasia: Combined infection amplifies BALT hyperplasia, contributing to airway obstruction
• Impaired mucociliary clearance: M. hyopneumoniae-induced ciliostasis compounds PRRSV-mediated macrophage dysfunction
• Altered immune polarization: Coinfection shifts cytokine profiles toward Th2/Th17 responses, reducing effective Th1-mediated viral clearance

Detection of infectious agents in lungs of slaughtered pigs with cranioventral pulmonary consolidation frequently reveals M. hyopneumoniae and PRRSV as the most prevalent dual detection [6]. This combination represents the archetypal PRDC presentation in finishing pigs.

3.3 Actinobacillus pleuropneumoniae

Actinobacillus pleuropneumoniae (APP) is a Gram-negative coccobacillus producing RTX toxins (ApxI, ApxII, ApxIII) that cause necrotizing hemorrhagic pneumonia. Fifteen serovars exist with variable virulence and geographic distribution. Longitudinal surveillance of APP isolates from diseased swine in northwestern Germany over a 15-year period revealed temporal patterns in coinfection prevalence and phenotypic antimicrobial resistance [13]. PRRSV coinfection increases the severity of APP-induced lesions through:

• Upregulation of host receptors for Apx toxins
• Suppression of neutrophil oxidative burst
• Disruption of endothelial barrier integrity

3.4 Other Significant Bacterial Pathogens

Additional bacterial agents frequently detected in PRRSV-coinfected pigs include:

• Glaesserella parasuis (formerly Haemophilus parasuis): Causes Glässer disease (polyserositis, arthritis, meningitis); virulence associated with capsule type and complement resistance
• Pasteurella multocida: Opportunistic pathogen exploiting damaged respiratory mucosa; type A strains predominant in swine
• Salmonella enterica serovar Choleraesuis: Systemic pathogen; PRRSV coinfection enhances intestinal invasion and systemic dissemination. A Bacillus-based direct-fed microbial was shown to reduce the pathogenic synergy of Salmonella Choleraesuis and PRRSV coinfection, suggesting microbiome modulation as a control strategy [12]
• Trueperella pyogenes: Secondary invader in chronic pneumonia and abscess formation

4. Diagnostic Challenges in Mixed Infections

4.1 Limitations of Conventional Diagnostics

The accurate diagnosis of PRDC is complicated by several factors:

1. Non-specific clinical signs: Coughing, dyspnea, fever, and reduced growth performance are common to multiple etiologies
2. Variable pathogen shedding: Viral and bacterial shedding kinetics differ temporally; a single sampling timepoint may miss one component
3. Sample quality dependence: Necropsy timing, sample type (lung lavage vs. tissue vs. nasal swab), and transport conditions affect detection sensitivity
4. Commensal vs. pathogenic distinction: Many PRDC bacteria are part of the normal upper respiratory flora; quantitative thresholds and virulence gene detection are required for interpretation

4.2 Molecular Multiplex Platforms

Multiplex nucleic acid amplification tests (NAATs) have become the standard for simultaneous detection of multiple respiratory pathogens. A multiplex ligation-dependent probe amplification (MLPA) assay was developed for detection and differentiation of seven porcine respiratory pathogens including PRRSV, M. hyopneumoniae, S. suis, A. pleuropneumoniae, G. parasuis, P. multocida, and swine influenza virus [10]. MLPA offers advantages over conventional multiplex PCR including:

• Reduced primer-dimer formation through probe-based detection
• Quantitative capability via probe signal intensity
• Tolerance for sequence variation in probe binding regions
• Compatibility with automated capillary electrophoresis platforms

High-throughput sequencing approaches, including metagenomic and targeted amplicon sequencing, provide comprehensive pathogen detection and characterization. A virome analysis of post-weaned diarrheic pigs and healthy cohorts in England demonstrated the utility of unbiased sequencing for detecting known and novel viral pathogens in complex clinical presentations [3]. Co-infection analysis of bacterial and viral respiratory pathogens from clinically healthy swine in eastern China revealed high rates of subclinical polymicrobial colonization, emphasizing the need for quantitative and contextual interpretation [15].

4.3 Diagnostic Algorithm for PRDC

flowchart TD
    A[Clinical Suspicion of PRDC], > B{Acute vs Chronic Presentation}
    B, >|Acute| C[Collect: Lung Lavage, Fresh Lung Tissue, Blood, Tonsil Swabs]
    B, >|Chronic| D[Collect: Lung Tissue Lesions, Serum, Nasal Swabs]
    C, > E[Multiplex NAAT Panel: PRRSV, SIV, PCV2, Mhp, App, Ss, Gp, Pm]
    D, > E
    E, > F{PRRSV Positive?}
    F, >|Yes| G[PRRSV Genotyping: ORF5 Sequencing]
    F, >|No| H[Evaluate Other Viral Pathogens]
    G, > I[Bacterial Culture + AST from Lesions]
    H, > I
    I, > J[Quantitative PCR for Bacterial Load]
    J, > K[Metagenomic Sequencing if Etiology Unclear]
    K, > L[Integrated Report: Pathogen Load, Virulence Genes, AMR Profile, Viral Lineage]
    L, > M[Treatment and Control Recommendations]

4.4 Antimicrobial Susceptibility Testing in Coinfection Context

Antimicrobial susceptibility testing (AST) of bacterial isolates from PRRSV-coinfected pigs presents interpretive challenges. The inflammatory milieu and tissue necrosis in coinfected lungs may alter antibiotic penetration and bacterial metabolic state, potentially discordant with in vitro susceptibility results. Standardized broth microdilution methods following CLSI veterinary guidelines (VET01) should be applied, with consideration for:

• Testing against antibiotics approved for swine respiratory disease
• Including pharmacokinetic/pharmacodynamic (PK/PD) breakpoints where established
• Monitoring for emerging resistance in A. pleuropneumoniae, S. suis, and P. multocida
• Evaluating biofilm-associated resistance for chronic M. hyopneumoniae infections

5. Pathogenesis of Specific Coinfection Syndromes

5.1 PRRSV and Streptococcus suis: Meningitis and Septicemia

The progression from respiratory coinfection to systemic S. suis disease involves bacterial translocation across the alveolar-capillary barrier, survival in bloodstream, and penetration of the blood-brain barrier. PRRSV facilitates this cascade through:

• Viremia-mediated endothelial activation: PRRSV infects pulmonary intravascular macrophages and endothelial cells, upregulating adhesion molecules (VCAM-1, ICAM-1) that promote bacterial adherence
• Thrombocytopenia and coagulopathy: PRRSV-induced platelet dysfunction and disseminated intravascular coagulation create microthrombi that serve as bacterial niduses
• Complement consumption: Classical pathway activation by immune complexes depletes complement components required for S. suis opsonophagocytosis

The resulting clinical syndrome includes acute septicemia, polyserositis, arthritis, and meningitis with high case fatality rates in nursery and growing pigs.

5.2 PRRSV and Mycoplasma hyopneumoniae: Chronic Enzootic Pneumonia

The chronic form of PRDC dominated by M. hyopneumoniae and PRRSV manifests as:

• Reduced average daily gain (ADG): 50-100 g/day reduction in finishing pigs
• Increased feed conversion ratio (FCR): 0.1-0.3 units increase
• Heterogeneous growth: Increased coefficient of variation in batch weights
• Cranioventral pulmonary consolidation: Characteristic lesions at slaughter

The economic impact is driven by subclinical infection in a high proportion of the herd rather than acute mortality.

5.3 PRRSV and Actinobacillus pleuropneumoniae: Acute Pleuropneumonia

Coinfection with APP serovars 1, 5, 9, 11 (ApxI+II+III producers) and PRRSV produces fulminant outbreaks with:

• Peracute death with minimal premonitory signs
• Fibrinonecrotic hemorrhagic pneumonia affecting diaphragmatic lobes
• Pleural adhesions and fibrinous pleuritis
• High morbidity (30-50 percent) and mortality (10-30 percent) in affected groups

6. Control Strategies

6.1 Vaccination Approaches

6.1.1 PRRSV Vaccines

Modified live virus (MLV) vaccines (PRRSV-1 and PRRSV-2) and inactivated vaccines are widely used. MLV vaccines induce cell-mediated immunity and partial heterologous protection but carry risks of reversion to virulence, vertical transmission, and recombination with field strains. Inactivated vaccines are safer but induce weaker cell-mediated immunity and require adjuvant optimization.

Recent advances include:

• Double-mutant attenuated strains: Engineered to reduce proinflammatory cytokine induction while maintaining immunogenicity [11]
• Vectored vaccines: Adenovirus, poxvirus, and Lactobacillus vectors expressing PRRSV GP5, M, and N proteins
• mRNA vaccines: Lipid nanoparticle-encapsulated mRNA encoding structural proteins; early experimental stage in swine
• Universal vaccine targets: Conserved epitopes in Nsp2, Nsp5, and GP4 under investigation

6.1.2 Bacterial Vaccines

• M. hyopneumoniae: Bacterins (inactivated whole-cell) and subunit vaccines (P97, P102, P146 adhesins); reduce lesion severity and bacterial load but do not prevent colonization
• A. pleuropneumoniae: Toxoid vaccines (ApxI, II, III) and bacterins; serovar-specific protection; autogenous vaccines for non-vaccine serovars
• S. suis: No commercial vaccine with broad cross-serotype protection; autogenous bacterins and experimental subunit vaccines targeting conserved surface proteins (Sao, GAPDH, enolase)

6.1.3 Combined Vaccination Protocols

Sequential or simultaneous administration of PRRSV MLV and bacterial vaccines requires careful timing to avoid immune interference. Studies suggest:

• PRRSV MLV vaccination at 1-3 weeks of age
• M. hyopneumoniae bacterin at 1 and 3 weeks (two-dose regimen)
• A. pleuropneumoniae toxoid at 3 and 5 weeks
• S. suis autogenous vaccine at weaning and 2 weeks later

6.2 Antimicrobial Stewardship

The introduction of PRRSV into a naïve farrow-to-finish system was associated with significant increases in antibiotic use in grow-finish pigs, particularly for respiratory disease treatment [9]. Strategic antimicrobial stewardship in PRDC includes:

• Targeted metaphylaxis: Based on diagnostic confirmation and epidemiological risk assessment rather than routine administration
• PK/PD-optimized dosing: Extended-interval dosing for concentration-dependent antibiotics (fluoroquinolones, macrolides); prolonged infusion for time-dependent antibiotics (β-lactams)
• Alternatives to antibiotics: Zinc oxide (pharmacological doses), organic acids, essential oils, and direct-fed microbials
• Diagnostic-guided de-escalation: Transition from broad-spectrum to narrow-spectrum therapy based on culture and AST results

The Bacillus-based direct-fed microbial that reduced pathogenic synergy in Salmonella Choleraesuis and PRRSV coinfection exemplifies the potential for microbiome-targeted interventions to reduce antibiotic dependence [12].

6.3 Biosecurity and Herd Management

6.3.1 Internal Biosecurity

• All-in/all-out (AIAO) flow: By room, building, or site; strict cleaning and disinfection between groups
• Age segregation: Physical separation of nursery, grower, and finisher phases
• Needle and equipment hygiene: Single-use needles per litter; dedicated equipment per age group
• Personnel protocols: Hand hygiene, boot changes, coverall changes between rooms

6.3.2 External Biosecurity

• Air filtration: MERV 15 or HEPA filtration for breeding herds in dense pig areas
• Transport sanitation: Thermal-assisted drying and heating (TADH) at 71°C for 30 minutes
• Supply entry: UV chambers, fumigation, or downtime for fomites
• Personnel downtime: Overnight downtime with shower-in/shower-out for high-health herds

6.3.3 Environmental Management

• Ventilation optimization: Minimum ventilation rates to reduce ammonia (<10 ppm) and carbon dioxide (<1500 ppm)
• Temperature control: Avoid chilling stress in weaned pigs; maintain thermoneutral zones
• Stocking density: Reduce density during PRRSV outbreaks to decrease contact rates
• Dust mitigation: Oil sprinkling, electrostatic precipitation, or wet feeding to reduce airborne bacterial load

6.4 Population Medicine Strategies

6.4.1 Herd Closure and Rollover

For PRRSV elimination in breeding herds:

• Herd closure: Cessation of replacement gilt introduction for 210-240 days
• Mass vaccination: Whole-herd MLV vaccination during closure
• Test and removal: Serial PCR testing of processing fluids, serum, or oral fluids to identify and remove persistent shedders
• Rollover: Introduction of PRRSV-naïve replacements after viral clearance confirmation

6.4.2 Regional Elimination Projects

Coordinated area-based PRRSV control involving:

• Shared surveillance data (ORF5 sequences, prevalence maps)
• Synchronized vaccination and herd closure schedules
• Coordinated pig flow and transport biosecurity
• Economic modeling of elimination vs. control costs

7. Computational and Systems Biology Approaches

7.1 Genomic Surveillance

Whole-genome sequencing of PRRSV and bacterial pathogens enables:

• Phylogenetic tracking: Identification of introduction events and transmission chains
• Recombination detection: Monitoring for novel recombinant strains with altered virulence
• Antimicrobial resistance prediction: Genotypic AMR profiling from whole-genome data
• Virulence gene profiling: Pan-genome analysis of bacterial populations

The integration of viral genomic surveillance with bacterial pathogen monitoring provides a holistic view of PRDC dynamics. Computational models for early detection and spread prediction, originally developed for African swine fever, are being adapted for PRRSV and associated bacterial pathogens [16].

7.2 Host-Pathogen Interaction Modeling

Systems biology approaches integrating transcriptomic, proteomic, and metabolomic data from coinfection models reveal:

• Network perturbation analysis: Identification of host pathways dysregulated by combined infection
• Predictive biomarkers: Early transcriptional signatures predictive of severe outcomes
• Drug target prioritization: Host-directed therapies modulating critical nodes in the interaction network

Biological foundation models for predicting host tropism and pathogenicity, developed for zoonotic viruses, are being extended to swine pathogens to forecast emergence risk and cross-species transmission potential [17, 18].

7.3 Machine Learning in Diagnostics

Machine learning algorithms trained on diagnostic laboratory data, production records, and environmental parameters can:

• Predict PRDC outbreak risk weeks in advance
• Classify cough sound patterns for automated respiratory disease monitoring
• Optimize sampling strategies for cost-effective surveillance
• Interpret complex multiplex PCR and sequencing results

8. Emerging Research Directions

8.1 Phage Therapy

Bacteriophages targeting S. suis, A. pleuropneumoniae, and P. multocida are under investigation as alternatives or adjuncts to antibiotics. Key challenges include:

• Narrow host range requiring phage cocktails
• Bacterial resistance development
• Regulatory approval pathways for veterinary phage products
• Stability and delivery in respiratory tract

8.2 Host Genetic Selection

Genome-wide association studies (GWAS) have identified quantitative trait loci (QTL) associated with:

• PRRSV resistance (e.g., GBP5 locus on chromosome 4)
• M. hyopneumoniae lesion resistance
• General respiratory disease resilience

Genomic selection for disease resilience is being implemented in nucleus breeding programs.

8.3 Immunomodulatory Interventions

• Type I interferon induction: Synthetic TLR agonists (poly I:C, CpG-ODN) administered intranasally to boost antiviral state
• Checkpoint inhibition: Anti-PD-1/PD-L1 antibodies to reverse T cell exhaustion in chronic PRRSV infection
• Trained immunity: β-glucan or BCG priming of innate immune memory in neonatal pigs

9. Conclusions

PRRSV coinfections with bacterial pathogens represent a multifactorial disease complex driven by viral immune suppression, bacterial virulence enhancement, and environmental cofactors. The synergistic pathogenesis involves molecular crosstalk at the level of macrophage function, epithelial integrity, cytokine networks, and microbiome composition. Diagnostic resolution requires multiplex molecular platforms with quantitative interpretation and antimicrobial susceptibility profiling. Control strategies must integrate vaccination, antimicrobial stewardship, biosecurity, and population medicine approaches tailored to herd-specific epidemiology. Advances in genomic surveillance, computational modeling, and host-directed therapeutics offer promising avenues for sustainable PRDC management. Continued investment in fundamental research on viral-bacterial interaction mechanisms and translational development of novel interventions is essential to mitigate the global burden of this disease complex.

References

[1] Zhao Z, Chu Y, Gong J et al. Lipid profiling of the secondary infecting bacteria with porcine reproductive and respiratory syndrome virus, including Streptococcus suis serotype 2, and their hosts. Microb Pathog. 20